Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "results"

2111 News Found

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%
News | February 11, 2026

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year


Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million
News | February 11, 2026

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025


Veradermics completes enrollment in both Phase 3 male hair loss trials
Clinical Trials | February 11, 2026

Veradermics completes enrollment in both Phase 3 male hair loss trials

The milestone means more than 1,000 men are now enrolled across both Phase 3 programs


Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion
News | February 10, 2026

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles


Zydus Lifesciences reports strong Q3 & 9M FY26 growth
News | February 10, 2026

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million


GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
News | February 10, 2026

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum


Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26
News | February 10, 2026

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year


SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
News | February 10, 2026

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%